As a leader in rare diseases and specialty care, Sobi is committed to improving the lives of patients. Sobi’s cost-efficient and integrated platform for commercialising products in Europe is leading the way in bringing products to patients in the region.
We provide a full range of services including strategies for regulatory approval, pricing and reimbursement, as well as preparations for additional and/or subsequent marketing activities, tender management and efficient logistics. We also have extensive capabilities and experience in the development and manufacture of biopharmaceuticals.
Our local and regional reach gives our partners access to over 70 countries with a total of more than 1 billion inhabitants.
Partnering with Sobi – a sustainable business model
The pan-European market consists of nearly 40 countries with a broad range of supply-chain demands, patient needs, health-care traditions and medical standards.
Companies entering Europe are often faced with two difficult options: to charge more for their product, which might slow or even eliminate their opportunities to receive reimbursement, or to not make the medication available at all in certain countries. Either decision will impact those in need of the medication: the patients. A cost-efficient platform for the provision of products for a limited number of patients is important, and has a direct impact on the availability of niche medications to European patients.
Sobi’s partnering model has been the basis for our successful haemophilia franchise as well as numerous other product launches over the years within varying indications. Partnering has also been a key innovation driver in our pipeline.
We are always open for new partnerships, particularly for product opportunities with a high degree of innovation, and which fulfil unmet medical needs, for in-licensing as well as acquisition.
If you are interested in finding out more, please call the Sobi Corporate Development Team on +46 8 697 20 00 for further assistance.